25th Sep 2024 14:30
Ondine Biomedical Inc - Vancouver-based company specialising in photodisinfection-based therapies - Announces research collaboration with the Royal Columbian Hospital Foundation's Advancing Innovation in Medicine division. RCH Foundation is an independent charitable organisation that funds priority equipment, major projects and other RCH needs. Says research collaboration is in support of Steriwave use in intensive care units, and is investigating Steriwave's impact on infection prevention and patient outcomes in critical care settings starting with a 320-patient pilot. Ondine says there is potential for a subsequent multicentre trial with up to 2,000 patients depending on pilot results.
AIM division will finance the CAD855,000 study. In return Ondine will issue new common shares in four tranches, the first of which will be satisfied upfront by the issue of 950,000 shares at 22.5 Canadian cents or 12.5 pence each. Expects collaboration to integrate Steriwave "into ICU infection control and workflow protocols, determining the impact of rapid broad spectrum nasal decolonisation on ICU infection rates, impact on length of stay and mortality rates".
Current stock price: 6.97p, up 3.3% on Wednesday afternoon in London
12-month change: down 25%
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.